BioVie (NASDAQ:BIVI) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of BioVie (NASDAQ:BIVI) to a sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioVie in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

BioVie Stock Performance

BIVI stock opened at $1.80 on Friday. The firm has a fifty day moving average price of $1.70 and a 200 day moving average price of $1.47. BioVie has a fifty-two week low of $1.06 and a fifty-two week high of $9.09. The firm has a market cap of $13.58 million, a PE ratio of -0.73 and a beta of 0.57.

BioVie (NASDAQ:BIVI) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.03.

Hedge Funds Weigh In On BioVie

Several hedge funds have recently bought and sold shares of BIVI. Renaissance Technologies LLC increased its stake in BioVie by 142.4% in the first quarter. Renaissance Technologies LLC now owns 67,918 shares of the company’s stock worth $95,000 after purchasing an additional 39,900 shares during the period. XTX Topco Ltd purchased a new stake in shares of BioVie during the fourth quarter valued at $25,000. DRW Securities LLC purchased a new stake in shares of BioVie during the fourth quarter valued at $149,000. Prosperity Wealth Management Inc. bought a new position in shares of BioVie in the third quarter worth about $273,000. Finally, Prelude Capital Management LLC bought a new position in shares of BioVie in the third quarter worth about $275,000. Institutional investors own 4.59% of the company’s stock.

About BioVie

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.